Literature DB >> 29307460

Diabetes Mellitus and Right Ventricular Dysfunction in Heart Failure With Preserved Ejection Fraction.

Thomas M Gorter1, Koen W Streng2, Joost P van Melle2, Michiel Rienstra2, Michael G Dickinson2, Carolyn S P Lam3, Yoran M Hummel2, Adriaan A Voors2, Elke S Hoendermis2, Dirk J van Veldhuisen2.   

Abstract

Diabetes mellitus is associated with left-sided myocardial remodeling in heart failure with preserved ejection fraction (HFpEF). Little is known about the impact of diabetes mellitus on right ventricular (RV) function in HFpEF. We therefore studied the relation between diabetes mellitus and RV dysfunction in HFpEF. We have examined patients with HFpEF who underwent simultaneous right-sided cardiac catheterization and echocardiography. RV systolic function was assessed using multiple established echocardiographic parameters, and systolic dysfunction was present if ≥2 parameters were outside the normal range. RV diastolic function was assessed using the peak diastolic tissue velocity of the lateral tricuspid annulus (RV e') and was present if <8.0 cm/s. Diabetes mellitus was defined as a documented history of diabetes, a fasting glucose level of ≥7.0 mmol/L, a positive glucose intolerance test result, or a glycated hemoglobin level of ≥6.5%. A total of 91 patients were studied (mean age 74 ± 9 years, 69% women). A total of 37% had RV systolic dysfunction and 23% RV diastolic dysfunction. Thirty-seven percent of the patients had type 2 diabetes mellitus. These patients had higher pulmonary artery pressure (34 mm Hg vs 29 mm Hg, p = 0.004), more RV systolic dysfunction (57% vs 29%, p = 0.009), more RV diastolic dysfunction (46% vs 12%, p = 0.001), and lower RV e' (8.7 cm/s vs 11.5 cm/s, p = 0.006). The presence of diabetes mellitus was independently associated with RV systolic dysfunction (odds ratio 2.84, 95% confidence interval 1.09 to 7.40, p = 0.03) and with RV diastolic dysfunction (odds ratio 4.33, 95% confidence interval 1.25 to 15.07, p = 0.02), after adjustment for age, gender, and pulmonary pressures. In conclusion, diabetes mellitus is strongly associated with RV systolic and diastolic dysfunctions in patients with HFpEF, independent of RV afterload.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 29307460     DOI: 10.1016/j.amjcard.2017.11.040

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Time to assess the effects of sodium-glucose co-transporter-2 inhibitors on the 'forgotten' right ventricle?

Authors:  Dimitrios Patoulias; Alexandra Katsimardou; Maria Toumpourleka; Christodoulos Papadopoulos; Michael Doumas
Journal:  ESC Heart Fail       Date:  2019-12-19

2.  Association of left ventricular longitudinal myocardial function with subclinical right ventricular dysfunction in type 2 diabetes mellitus.

Authors:  Saki Todo; Hidekazu Tanaka; Yuki Yamauchi; Shun Yokota; Yasuhide Mochizuki; Hiroaki Shiraki; Kentaro Yamashita; Ayu Shono; Makiko Suzuki; Keiko Sumimoto; Yusuke Tanaka; Yushi Hirota; Wataru Ogawa; Ken-Ichi Hirata
Journal:  Cardiovasc Diabetol       Date:  2021-10-23       Impact factor: 9.951

3.  Epicardial adipose tissue and right ventricular function in type 2 diabetes mellitus using two-dimensional speckle tracking echocardiography.

Authors:  Xiang-Ting Song; Ping-Yang Zhang; Li Fan; Yi-Fei Rui
Journal:  Diab Vasc Dis Res       Date:  2022 Jul-Aug       Impact factor: 3.541

Review 4.  Ketone body metabolism in diabetic and non-diabetic heart failure.

Authors:  Ningjing Qian; Yaping Wang
Journal:  Heart Fail Rev       Date:  2020-09       Impact factor: 4.214

5.  Associations of (pre)diabetes with right ventricular and atrial structure and function: the Maastricht Study.

Authors:  Pauline B C Linssen; Marja G J Veugen; Ronald M A Henry; Carla J H van der Kallen; Abraham A Kroon; Miranda T Schram; Hans-Peter Brunner-La Rocca; Coen D A Stehouwer
Journal:  Cardiovasc Diabetol       Date:  2020-06-15       Impact factor: 9.951

6.  Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes.

Authors:  Bradley Sarak; Subodh Verma; C David Mazer; Hwee Teoh; Adrian Quan; Richard E Gilbert; Shaun G Goodman; Karan Bami; Otávio R Coelho-Filho; Vineeta Ahooja; Djeven P Deva; Vinay Garg; Sumeet Gandhi; Kim A Connelly; Andrew T Yan
Journal:  Cardiovasc Diabetol       Date:  2021-10-04       Impact factor: 9.951

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.